Increasing age has been reported to be associated with worse outcome and higher occurrence of complication after allogeneic bone marrow transplantation. We analysed a cohort of 39 patients between the ages of 45 and 57 (median 49 years) with different hematologic malignancies who had undergone BMT in our institution over the preceeding 4 years. Pretransplant conditioning consisted of Bu/CY2, GVHD prophylaxis of a combination of cyclosporine and 'short' methotrexate. At present 54% of patients remain alive (with a median follow-up 44 months), the probability of survival at 5 years is 53% (5-year DFS 78%). The 5-year survival probability in the control group of younger patients is 53% (P = 0.8003). Main causes of death were GVHD (4 patients, 10%), relapse (5 patients, 13%) and infection (6 patients, 15%). The incidence of acute GVHD grade II-IV was 51% (grade III-IV 0% patients), the incidence of chronic GVHD 49% (limited 18% and extensive 31% patients). Our results suggest that allogeneic BMT can be performed in patients above the age of 45 years with acceptable morbidity and mortality, especially if a family HLA matched donor is available. Bone Marrow Transplantation (2001) 27, 723-726.
Allogeneic bone marrow transplantation is an effective therapeutic modality for patients with hematologic malignancies who are otherwise incurable. It has been previously reported that increasing age is a risk factor associated with a higher incidence of morbidity and mortality after bone marrow transplantation. 1, 2 Because of the adverse association between age and outcome after BMT, many centers limit transplants to patient less than 45 years old. [1] [2] [3] However this approach excludes older patients, often with poor prognosis diseases, who could benefit from an allogeneic BMT. A marked improvement in the results of BMT in recent years has been noted, above all in connection with a lowered transplant-related mortality rate, mainly because of better supportive care, better infection prophylaxis and treatment, and improved HLA-typing techniques. Some publications have reported that the outcomes of allogeneic BMT in patients over the age of 45 years were comparable to those in younger patients. [1] [2] [3] [4] We report out single centre experience with BMT in older patients. The purpose of our retrospective analysis was to determine the frequency of transplant-related complications and the survival rate and causes of death in patients above 45 years of age who underwent allogeneic bone marrow transplantation in our institution.
Patients and methods
Thirty-nine consecutive patients above 45 years of age with different hematological diseases underwent allogeneic BMT in our institution from June 1994 to December 1998. Median age of the monitored population was 49 years (range 45-57). Table 1 /kg (range 1.72-8.16). As an alternative to bone marrow, eight of the patients were transplanted with peripheral blood progenitor cells from donors stimulated with G-CSF.
Graft-versus-host disease prophylaxis consisted of cyclosporine and 'short' methotrexate. 6 GVHD prophylaxis finished about 6 months after transplantation. Clinical acute GVHD was graded according to published criteria 7 and patients who developed acute GVHD were treated with corticosteroids. Chronic GVHD was diagnosed according to the criteria of Shulman et al. 8 G-CSF 5 g/kg/day was given after BMT to 16 patients. All patients received prophylactic antimicrobial therapy from admission until discharge from hospital. Patients were housed in single-bed rooms with HEPA-filtered air. Overall survival was calculated from the day of marrow infusion until death from any cause. Transplant-related mortality (TRM) was defined as any non-relapse death until day +100. Disease-free survival was defined as survival without evidence of disease.
Statistical analysis
Variables between the two age groups were compared using the Fisher's exact test. Comparisons of survival probabilities were performed using the logrank test. All analyses were performed using the GraphPad InStat and GraphPad Prism software package.
Results
At the time of data analysis, follow-up times ranged from 22 to 74 months (median 44 months). Engraftment was achieved in 97% of patients; one patient died too early to evaluate engraftment (on day +7). The median time to reach an ANC above 0.5 × 10 Ten patients (26%) developed clinical evidence of VOD of the liver, but this complication was lethal in only one. The incidence of acute GVHD grades II-IV was 51% (grades III-IV 0%). Infectious complications up to day +100 were as follows: bacteraemia 74% patients, fungal infections 15% patients, viral infection 10% patients and FUO 18% patients. Chronic GVHD occurred in 49% of patients (limited 18% and extensive 31%). After day +100 the following infectious complications were recorded: bacterial 23% patients, viral 23% patients and fungal 3% patients. Data are shown in Tables 2 and 3 .
Transplant-related mortality was 10% (four patients): aGVHD two patients, infection one patient, VOD one patient. The main causes of death up to the day of analysis were GVHD (10%), relapse (13%) and infection (15%). One patient died of graft failure (2.6%), one of severe VOD (2.6%) and one of intracranial bleeding (2.6%). The 5-year survival rate was 53%) (Figure 1 ). Seventeen patients are surviving without any complications (Karnofsky score over 80%), four with chronic GVHD. There was a marked influence of disease status on survival. 67% of patients transplanted in CR/PR of acute leukemia or chronic phase of CML are alive vs 0% patients who were in an advanced stage of their disease (Ͼ1st CP, Ͼ1st CR/PR) before transplantation. No significant impact of number of infused CD34 cells was recorded. The incidence of relapse was 15% (six patients, mainly with AL, one with CML). In the more homogenous group comprising 18 CML patients 5-year survival was 64% (data not shown).
We compared these data with BMT results from younger individuals (39 patients) aged р45 years (median 35 years). The range of diagnoses (CML 21, AML 13, ALL 4, MDS 1 patient) and patient characteristics were comparable to those in study population. Age was the only difference. Median follow-up was 48 months. The 5-year overall survival was 53% (P = 0.8003). Main reasons for death were GVHD (4 patients, 10%), relapse (7 patients, 18%) and infection (5 patients, 13%). The rate of acute GVHD grade II-IV was 33% and chronic GVHD 21%. Five-year survival, causes of death and incidence of acute GVHD were not significantly different between the two age troups. The incidence of chronic GVHD appeared to be higher in the Ͼ45 years group (49% vs 21%, P = 0.0165).
Discussion
It has been presumed that older patients will tolerate the intensive transplant procedure worse and that their treatment will be associated with a higher morbidity and mortality than that of a younger patient population.
1,2,9 Some institutions impose an age limit of 45-50 years for BMT. [1] [2] [3] But about half of all patients with leukemia are above 50 years of age 3 so such an approach tends to exclude older patients from this kind of therapy, which can often be the only approach likely to be effective. There are too few data defining a maximum acceptable age. Several studies on patients у40 years have shown that there is no significant differnce in transplant-related mortality, DFS or OS compared to younger adults. [1] [2] [3] [4] 9, 10 Determination of a precise upper age limit is certainly difficult and the limit appears to have moved upwards mainly because of improvements in supportive care, HLA typing, diagnosis and treatment of infections, complications and so on.
If our patients Ͼ45 years of age had poor risk disease (inability to achieve complete remission following standard induction chemotherapy, chromosomal abnormalities, etc), Karnofsky performance status was у80%, organ functions were normal and a suitable HLA-identical sibling donor was available, transplantation was offered. There was no evidence that older patients had any problems with engraftment. In previous studies older patients, and patients with older donors, have been reported to be at higher risk of acute and chronic GVHD and the associated mortality than are younger patients. [11] [12] [13] [14] [15] [16] Our results are consistent with these findings. Particularly the rate of chronic GVHD seems to be higher in comparison with our group of younger individuals. In younger patients (Ͻ45 years) frequency of acute GVHD grade II-IV was 33% (vs 51% in the older group) and frequency of chronic GVHD was 21% (vs 49%).
In our center, 54% of patients undergoing allogeneic BMT over 45 years of age currently remain alive at least 3 years after BMT. There is no obvious difference in comparison with our historical group of younger patients aged р45 years. Also, the main causes of death were similar in both groups of patients (Ͼ45 years and р45 years): GVHD (10% vs 10% patients), infection (15% vs 13% patients) and relapse (13% vs 18% patients).
Allogeneic BMT is the only known curative treatment for chronic myelogenous leukemia. Standard treatment with busulfan, hydroxyurea or interferon can control the symptoms of CML, but do not influence the natural history of the disease. 17 Allogeneic BMT can produce long-term disease-free survival in 40-80% patients with CML in chronic phase. [18] [19] [20] [21] [22] Among our patients with CML in chronic phase and a median age of 49 years, the 5-year probability of survival is 64%. The 3-year probability of relapse after allogeneic BMT for CML in CP is in the range of 10 to 30%. 21 The low incidence of relapse in our group of patients (only one patient) perhaps relates to the higher frequency of GVHD. On the other hand, GVHD was considered one of the main reasons for mortality in our cohort of patients. Maybe longer lasting post-transplant immunosuppression (longer than 6 months) might be advantageous in these patients and might reduce the incidence of GVHD and late transplant-related mortality.
Transplant-related mortality and overall survival rates for patients over the age у45 years remain within the accepted range of transplantation outcomes reported for younger adults. We conclude that older patients should not be denied this treatment based on age alone. The indication should be based on careful and individual assessment of patient's clinical condition. The search for a suitable family donor should be started immediately with the aim of performing the transplant while the patient is in the chronic phase of CML or is in a stable CR and is in good general condition. Our practice should be to selected patients for transplantation in the light of their disease characteristics and performance status and not only in respect of age.
